Colorectal Cancer Comparative Audit Report

Size: px
Start display at page:

Download "Colorectal Cancer Comparative Audit Report"

Transcription

1 SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT Colorectal Cancer Comparative Audit Report Mr B.J. Mander, NHS Lothian, Lead Colorectal Cancer Clinician, SCAN Group Chair Mr K Pal, NHS Borders Mr S Whitelaw, NHS Dumfries & Galloway Mr S Yalamarthi, NHS Fife Mr R G Wilson, NHS Lothian Dr H Philips, Clinical Oncologist, NHS Lothian Sarah Buchan SCAN Colorectal Cancer Audit Facilitator Lynn Smith, Cancer Audit Facilitator, NHS Borders Laura Halliday, Cancer Audit Facilitator, NHS Dumfries & Galloway Maureen Lamb, Cancer Audit Facilitator, NHS Fife Report No: SA CO1/16 SCAN Audit Office, Clinical Oncology, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU T: W: lorna.bruce@luht.scot.nhs.uk

2 COLORECTAL CANCER COMPARATIVE AUDIT REPORT Patients diagnosed 1 April March 2015 Table of Contents Document History... 4 Comment by Chair of the SCAN Colorectal Group... 5 Action Points... 6 Summary of Quality Performance Indicators:... 7 Introduction and Methods Data Quality Estimated Case Ascertainment Actions for Improvement Diagnosis and Staging QPI 1: Radiological Diagnosis and Staging (i) QPI 1: Radiological Diagnosis and Staging (ii) QPI 2: Pre-Operative Imaging of the Colon QPI 3: Multi-Disciplinary Team (MDT) Meeting QPI 4: Stoma Care Surgical Outcomes QPI 5: Lymph Node Yield QPI 6: Neoadjuvant Radiotherapy QPI 7: Surgical Margins (i) QPI 7: Surgical Margins (ii) QPI 8: Re-operation Rates QPI 9: Anastomotic Dehiscence (ii) QPI 10 (i): 30 Day Mortality Following Surgical Resection Elective Surgery QPI 10 (i): 30 Day Mortality Following Surgical Resection Emergency Surgery QPI 10 (ii): 90 Day Mortality Following Surgical Resection Elective Surgery QPI 10 (ii): 90 Day Mortality Following Surgical Resection Emergency Surgery Oncological Treatment Outcomes QPI 11: Adjuvant Chemotherapy QPI 11: Adjuvant Chemotherapy Dukes C QPI 12 (i): 30 Day Mortality Following Chemotherapy or Radiotherapy QPI 12 (ii): 90 Day Mortality Following Chemotherapy or Radiotherapy Clinical Trials Clinical Trials Access Interventional Clinical Trials Clinical Trials Access Translational Research Key Categories Glossary

3 DOCUMENT HISTORY Version Circulation Date Comments D&G comments Lead Clinicians Sign Version 1 05/11/2015 required. BGH off Meeting corrections Version 2.1 SCAN Colorectal Group Members 12/01/2016 D&G comments added. BGH corrections made. Version 3 Health Board Clinical Governance Groups and to the RCPG. Also numbered and lodged on the audit report index 01/02/2016 Consideration by Lead Clinicians of any comments received from Clinical Governance Groups or RCPG. Audit staff assess report for risk of disclosing any sensitive personal information. Amendments made as required. Version 3W (for website) prepared. Version 3W Version 3W lodged on website after elapse of suitable length of time 4

4 Comment by Chair of the SCAN Colorectal Group This report provides comprehensive data on the management of colorectal cancer in the South East of Scotland from 1 st April st March Once again the SCAN Audit Team and Sarah Buchan in particular, have worked extremely hard to produce data of consistently high quality. This has been facilitated by local data collection teams. SCAN Colorectal Data has been submitted to the UK and Ireland Large Bowel Cancer Audit allowing for direct comparisons with the whole of the British Isles ( SCAN data holds up extremely well in comparison to other UK areas in terms of surgical outcomes. During 2014 in SCAN 932 patients were diagnosed with colorectal cancer. This represents an almost identical number of cancers as treated the previous year an approximately a 6% decrease on 2010 which may represent the plateau of increased incidence predicted by the introduction of bowel screening. Nonetheless we are managing over 20% more colorectal cancers in the region than we were in Of the 932 patients 649 (70%) underwent surgery, which was performed with curative intent in 90% of cases. Nearly 20% of the patients who had surgery were treated as emergencies. Despite the substantial increase in workload the exceptional standard of surgical care across the region has been maintained. Perioperative mortality for all patients undergoing elective surgery was 0.6% (which compares favourably with the UK audit average 30 day mortality rate of 3.7%. Complications caused by anastomotic dehiscence (leakage at the site of the surgical join) are very low (1.3% for colonic anastomosis, 2.2% for rectal anastomosis,). They fall well within the required national NHSQIS standards of 5% and 10% respectively and are the lowest level we have ever recorded in the region. We have seen a steady rise in the percentage of cases treated laparoscopically within SCAN and within a relatively brief period of time we have got the percentage of patients within the region whose operation is intended to be completed laparoscopically up to over 40% which is the UK average. 60 patients were treated with minimally invasive endoluminal techniques involving either endoscopic resection or Transanal Endoscopic Microsurgery (TEMS). This is the second year we have submitted data to the Colorectal Quality Performance Indicator Programme. In the vast majority of areas the targets have been met across the entire SCAN area. In a few cases where performance has not met the targets substantial progress has been made. Specific issues apposite to individual targets are discussed in the relevant sections and the strive for continuous quality improvement remains at the forefront of all the groups activities. Mr B.J. Mander Chair SCAN Colorectal Group Jan 16 5

5 ACTION POINTS Action Points from QPI QPI 1 (i) QPI 1 (ii) Action required Change in practice at Radiology for emergency patients who are not undergoing CT chest preoperatively. Ensure all patients upper rectal or rectosigmoid tumours undergo a pre-operative MRI, along with CT scan of chest, abdomen and pelvis. Person Responsible SCAN Colorectal Lead Clinicians SCAN Colorectal Lead Clinicians Progress at Board Level Fully implemented in Lothian and Fife. No requirement for change in D&G. Action agreed in Borders. Fully implemented in Borders Fife and Lothian. Discussions to be held in D&G QPI 2 QPI 4 QPI 5 Recommend all elective patients, who are unable to have colonoscopy, should have CT colonoscopy preoperatively. Ensure all patients at risk of a stoma meet a Stoma Nurse pre-operatively. The CRM (circumferential resection margin) should be recorded in all pre-operative imaging. SCAN Colorectal Lead Clinicians Colorectal Lead Clinicians in Lothian and Dumfries & Galloway SCAN Colorectal Lead Clinicians Fully implemented in Borders, Fife and Lothian. Discussions to be held in D&G Fully implemented in Borders and Fife. D&G: MDT system development in progress with expected completion date of 31/03/2015. Lothian: Active discussion initiated to consider preoperative marking of all anterior resections Fully implemented in Borders, Fife and Lothian. Discussions to be held in D&G. Action Points from QPI Action required Person Responsible Date for update QPI 1 (ii) Liaise with D&G regarding the policy of this QPI. Mr B J Mander, Lead Clinician SCAN March 2016 QPI 2 All Boards to disseminate requirement for appropriate pre-operative imaging of colon and need for CT Colon if endoscopic imaging is incomplete. All Lead Clinicians, SCAN March 2016 QPI 4 D&G and Lothian to continue to work with their respective Stoma Service to facilitate improvements Mr B J Mander, Lead Clinician, Lothian. Mr Whitelaw, Lead Clinician, D&G March 2016 QPI 7 (ii) D&G to review clinical management of patients with positive margins Mr Whitelaw, Lead Clinician, D&G March

6 Summary of Quality Performance Indicators: Target % % % % % % QPI 1 Radiological Diagnosis and Staging i) Patients with colon cancer who undergo CT chest, abdomen and pelvis before definitive treatment ii) Patients with rectal cancer undergoing definitive treatment (chemoradiotherapy or surgical resection) who undergo CT chest, abdomen and pelvis and MRI pelvis before definitive treatment QPI 2 Pre-Operative Imaging of the Colon Patients with colorectal cancer undergoing surgical resection should have the whole colon visualised pre-operatively QPI 3 - Multi-Disciplinary Team (MDT) MDT Meeting Patients with newly diagnosed colorectal cancer should be discussed by a MDT prior to definitive treatment NOT MEASURED QPI 4 Stoma Care Patients with colorectal cancer who require a stoma are assessed and have their stoma site marked pre-operatively by a nurse with expertise in stoma care QPI 5 Lymph Node Yield In patients undergoing resection for colorectal cancer the number of lymph nodes examined should be maximised QPI 6 Neoadjuvant Radiotherapy Patients with locally advanced rectal cancer should receive neo-adjuvant chemoradiotherapy designed to facilitate a margin-negative resection

7 QPI 7 Surgical Margins Target % % % % % % Rectal cancers undergoing surgical resection should be adequately excised (i) Primary surgery, or surgery following neo-adjuvant short course radiotherapy < < (ii) Surgery following neo-adjuvant long course radiotherapy or chemoradiotherapy < < QPI 8 Re-operation Rates For patients undergoing surgery for colorectal cancer re-operation should be minimised Elective Index Procedure < < Emergency Index Procedure < < QPI 9 Anastomotic Dehiscence For patients undergoing surgical resection for colorectal cancer anastomotic dehiscence should be minimised. (i) Colonic anastomosis < < (ii) Rectal anastomosis < (iii) Anterior resection with total mesorectal excision (TME) (ii) Rectal anastomosis inc anterior resection with total mesorectal excision (TME) < < QPI and 90 Day Mortality following Surgical Resection Mortality after surgical resection for colorectal cancer Elective Procedure < days < days < Emergency Procedure < days < days <

8 Target % % % % % % QPI 11 Adjuvant Chemotherapy Patients with Dukes C and high risk Dukes B colorectal cancer should be considered for adjuvant chemotherapy. High Risk Dukes B n/a Dukes C QPI and 90 day Mortality following Chemotherapy or Radiotherapy Mortality after chemotherapy or radiotherapy with curative intent for colorectal cancer < day mortality < day mortality <

9 Introduction and Methods Cohort and Personnel This report is the eleventh to present comparative data on patients newly diagnosed with colorectal cancer in South East Scotland Cancer Network (SCAN) at the following hospitals: Borders General Hospital (NHS Borders), Dumfries and Galloway Royal Infirmary (NHS Dumfries & Galloway), Victoria Hospital, Kirkcaldy (NHS Fife), St John's Hospital at Howden, Livingston, and Western General Hospital, Edinburgh (NHS Lothian). The report covers data on patients newly-diagnosed in the twelve months from 1 April 2014 to 31 March Lead Clinicians and staff involved in audit were as follows Borders General Hospital (BGH) Mr K Pal Lynn Smith Dumfries & Galloway Royal Infirmary (DGRI) Mr S Whitelaw Laura Halliday Victoria Hospital (Fife) Mr S Yalamarthi Maureen Lamb Western General Hospital, Edinburgh (WGH) Mr BJ Mander Sarah Buchan SCAN Mr BJ Mander Sarah Buchan Audit Processes and data recording Collection of the nationally-agreed core minimum dataset continues in all hospitals in South East Scotland. Data capture is focused round the process for the weekly multidisciplinary meetings i.e. ensuring that data covering patient referral, investigation, and diagnosis is being picked up through the routine process. Surgical and Oncology data is obtained either from the clinical records (electronic systems and case notes) or by download from the Department of Clinical Oncology database within the Edinburgh Cancer Centre (ECC) The process remains dependent on audit staff for capture and entry of data, and for data quality checking 3.4 Data was recorded on TRAK in Lothian. In Borders, Fife and Dumfries & Galloway data was collected using E-case. 10

10 Dataset and Definitions The QPIs have been developed collaboratively with the three Regional Cancer Networks, Information Services Division (ISD), and Healthcare Improvement Scotland. QPIs will be kept under regular review and be responsive to changes in clinical practice and emerging evidence. The overarching aim of the cancer quality work programme is to ensure that activity at NHS board level is focussed on areas most important in terms of improving survival and patient experience whilst reducing variance and ensuring safe, effective and person-centred cancer care. Following a period of development, public engagement and finalisation, each set of QPIs is published by Healthcare Improvement Scotland 1. Accompanying datasets and measurability criteria for QPIs are published on the ISD website 2. NHS boards are required to report against QPIs as part of a mandatory, publicly reported, programme at a national level. The QPI dataset for Colorectal was implemented from 01/04/2013, and this is the second publication of QPI results for colorectal cancer within SCAN. The standard QPI format is shown below: QPI Title: Description: Rationale and Evidence: Specifications: Target: Short title of Quality Performance Indicator (for use in reports etc.) Full and clear description of the Quality Performance Indicator. Description of the evidence base and rationale which underpins this indicator. Numerator: Denominator: Of all the patients included in the denominator those who meet the criteria set out in the indicator. All patients to be included in the measurement of this indicator. Patients who should be excluded from measurement of this Exclusions: indicator. Include in the denominator for measurement against the target. Not recorded for Present as not recorded only if the patient cannot otherwise be numerator: identified as having met/not met the target. Include in the denominator for measurement against the target unless there is other definitive evidence that the record should Not recorded for be excluded. Present as not recorded only where the record exclusion: cannot otherwise be definitively identified as an inclusion/exclusion for this standard. Exclude from the denominator for measurement against the Not recorded for target. Present as not recorded only where the patient cannot denominator: otherwise be definitively identified as an inclusion/exclusion for this standard. Statement of the level of performance to be achieved. 1 QPI documents are available at 2 Datasets and measurability documents are available at 11

11 Data Quality Clinical Sign-Off: This report compares data from reports prepared for individual hospitals and signed off as accurate following review by the lead clinicians from each service. Additionally, the collated SCAN results are reviewed jointly by the lead clinicians, including the lead Oncologist, to assess variances and provide comments on results. External QA: SCAN Audit participates in external quality assurance (QA) of data by ISD Scotland, (i.e. when a sample of data is compared with the data definitions). A QA of the QPI colorectal dataset took place in February Estimated Case Ascertainment: Case ascertainment has been estimated using Scottish Cancer Registration data for comparison purposes. Tables on case ascertainment and five year averages are contained in the next section. Most patients are identified through weekly multidisciplinary meetings. The following sources are used to check for missing patients: 1. Pathology records 2. GRO Death lists 3. Dept of Clinical Oncology retrospective database 4. Clinical Nurse Specialist database 12

12 ESTIMATE OF CASE ASCERTAINMENT Estimated Case Ascertainment An estimate of case ascertainment (the percentage of the population with colorectal cancer recorded in the audit) is made by comparison with the Scottish Cancer Registry five year average data from 2010 to High levels of case ascertainment provide confidence in the completeness of the audit recording and contribute to the reliability of results presented. Levels greater than 100% may be attributable to an increase in incidence. Allowance should be made when reviewing results where numbers are small and variation may be due to chance. Number of cases recorded in audit: patients diagnosed to Colon cancer Rectal cancer Total Estimate of case ascertainment: calculated using the average of the most recent available five years of Cancer Registry Data Cases from Audit Cancer Registry 5 Year Average Case Ascertainment % Actions for Improvement After final sign off, the process is for the report to be sent to the Clinical Governance groups within the four health boards and to the Regional Cancer Planning Group. Action plans and progress with plans will be highlighted to the groups. The report will be placed on the SCAN website once it has been fully signed-off and checked for any disclosive material. Sarah Buchan SCAN Audit Facilitator Source: Scottish Cancer Registry, ISD. Data extracted from ACaDMe Note: Case ascertainment is reported by board of diagnosis and has been estimated using a denominator based on the latest ( ) five-year annual average available from the Scottish Cancer Registry. Death certificate only cases have been excluded. Cases that have been diagnosed in the private sector but received any treatment in NHS hospitals have been included. 13

13 DIAGNOSIS AND STAGING QPI 1: Radiological Diagnosis and Staging (i) Target = 95% Numerator = Number of patients with colon cancer who undergo CT chest, abdomen and pelvis before definitive treatment. Denominator = All patients with colon cancer Exclusions = (a) Patients who refuse investigations (b) Patients who undergo emergency surgeryª (c) Patients undergoing supportive care. Patients with colon cancer who undergo staging investigations before definitive treatment Borders N D&G N Fife N Lothian N SCAN N Cohort Ineligible for this QPI Target 95% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusion Not Recorded for Denominator % Performance 100.0% 97.1% 95.3% 98.4% 97.6% This QPI was met in all Boards 14

14 QPI 1 (i) Colon Cancer - Pre-op Staging 100 % Patients Patients undergoing pre-op staging investigations QPI Target 20 0 Borders D&G Fife Lothian Scan Health Board Comments: These results show the high standard of pre-operative imaging in all Boards. 15

15 QPI 1: Radiological Diagnosis and Staging (ii) Target = 95% Numerator = All patients with rectal cancer undergoing definitive treatment (chemoradiotherapy or surgical resection) who undergo CT chest, abdomen and pelvis and MRI pelvis before definitive treatment. Denominator = All patients with rectal cancer undergoing definitive treatment (chemoradiotherapy or surgical resection). Exclusions = (a) Patients who refuse investigations (b) Patients who undergo emergency surgeryª (c) Patients with a contraindication to MRI. Patients with rectal cancer undergoing staging investigations before definitive treatment N N N N N Cohort Ineligible for this QPI Target 95% Numerator Not Recorded for Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Recorded 94.7% 50.0% 90.0% 89.2% 85.7% Comments where QPI not met Borders: 1 Patient: an incompletely excised polyp then went on for resection. D&G: 9 Patients: 4 had recto-sigmoid tumours and MRI was not performed. 2 had no documented reasons as to why MRI was not performed. 2 had high grade dysplasia on biopsy (1 went on to have MRI post-treatment). 1 had a high rectal cancer and no MRI was performed. Fife: 5 patients: 4 were thought to be recto-sigmoid and found to be rectal at surgery and no MRI was performed. 1 was under review for ulcerative colitis and was an incidental Dukes A on surgery. Lothian: 8 patients: 4 thought to be distal sigmoid on CT. 2 had proven metastases so MRI wound not have changed management. 1 had a synchronous rectal tumour diagnosed at surgery for sigmoid cancer. 1 primary was difficult to see on CT?upper rectal. ª Emergency surgical resection is defined by the Consultant in Charge of the patient s care 16

16 QPI 2 Pre-op Visualisation of Colon % Patients Pre-op Staging of Colon QPI Target 20 0 Health Board Comment: This has been a challenging QPI because of the difficulties in localising upper rectal tumours confidently. The vast majority of patients not meeting the QPI had imaging discussed at the Multi-Disciplinary Meeting and MRI was not felt to be necessary. 17

17 QPI 2: Pre-Operative Imaging of the Colon Target = 95% Numerator = Number of patients who undergo elective surgical resection for colorectal cancer who have the whole colon visualised by colonoscopy or CT colonography before surgery, unless the non-visualised segment of colon has been removed. Denominator = All patients who undergo elective surgical resection for colorectal cancer Exclusions = No exclusions Elective Colorectal Patients undergoing Surgical Resection have the whole colon visualised by colonoscopy/ct colonography preoperatively, unless the non-visualised segment has been removed N N N N N Cohort Ineligible for this QPI Target 95% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for the Denominator % Percentage 95.7% 80.0% 80.9% 92.5% 88.2% Comments where QPI not met Borders: 2 patients: both had flexible sigmoidoscopy as colonoscopy was limited by tumour and excess looping causing patient discomfort D&G: 15 patients: 7 had incomplete colonoscopies. 5 had flexible sigmoidoscopy. 2 had CT colons were requested, 1 did not attend and 1 was not completed (radiology vetting error) 1 had CT abdomen diagnosis but was at risk of obstruction so no scope was performed. Fife: 25 patients: 16 incomplete colonoscopies - all limited by tumour. 8 not performed - 9 had flexible sigmoidoscopy and 3 went straight to surgery. Lothian: 21 patients: 16 had incomplete colonoscopies. 4 had no colonic imaging (one of whom had contraindications for CT colon). 1 had flexible sigmoidoscopy only. 18

18 QPI 2 Pre-op Visualisation of Colon % Patients Pre-op Staging of Colon QPI Target 20 0 Health Board Comment: There has been a small improvement across SCAN in this QPI. Nearly all patients were endoscoped to the tumour. Further discussions should be held locally to facilitate an increase in patients undergoing complete colonic imaging either by colonoscopy or CT colon. 19

19 QPI 3: Multi-Disciplinary Team (MDT) Meeting Target = 95% Numerator = Number of patients with colorectal cancer discussed at the MDT before definitive treatment. Denominator = All patients with colorectal cancer. Exclusions = Patients who died before first treatment, patients undergoing emergency surgery and patients undergoing treatment with endoscopic polypectomy only. All patients diagnosed with colorectal cancer (excluding patients who died before first treatment patients undergoing emergency surgery and patients undergoing treatment with endoscopic polypectomy only). N N N N N Cohort Ineligible for this QPI Target 95% Numerator Not Recorded for Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Recorded 100.0% 93.2% 97.2% 98.3% 97.5% Comments where QPI not met D&G: 6 patients: 4 had high grade dysplasia on biopsy. 1 was an unexpected cancer and 1 had palliative care and died within 6 days of emergency admission. 20

20 QPI 3: Multi-Disciplinary Team Meeting % Patients MDT Meeting QPI Target 20 0 Health Board Comment: This is the first year this QPI has been measured. Overall SCAN is meeting the target for this QPI. 21

21 QPI 4: Stoma Care Target = 95% Numerator = Number of patients with colorectal cancer who undergo elective surgical resection which involves stoma creation who are seen by and have their stoma site marked preoperatively by a nurse with expertise in stoma care. Denominator = All patients with colorectal cancer who undergo elective surgical resection which involves stoma creation. Exclusions = Patients who refuse to be seen by a nurse with expertise in stoma care. Number of patients with colorectal cancer undergoing elective surgical resection which involves stoma creation are seen by and have their stoma site marked pre-operatively by a Stoma Care Nurse Borders N D&G N Fife N Lothian N SCAN N Cohort Ineligible for this QPI Target 95% Numerator Not Recorded for Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Recorded 100.0% 76.5% 97.0% 89.2% 90.9% Comments where QPI not met D&G: 4 patients: 2 were not seen by stoma nurse and 2 were unplanned stomas at surgery Lothian: 7 patients: 6 had no stoma sited pre-surgery and 1 was unplanned stoma at surgery. 22

22 QPI 4: Stoma Care 100 % Patients Patients seen by Stoma Nurse Preoperatively QPI Target 20 0 Health Board Comment: There has been a slight improvement overall in SCAN in this QPI. Since these results stoma booking arrangements have been changed in Dumfries & Galloway, along with including stoma skill in the proposed ERAS nurses job description. In Lothian, there were some unexpected stomas but work will continue with the Stoma Nurses to improve the service. 23

23 SURGICAL OUTCOMES QPI 5: Lymph Node Yield Target = 80% Numerator = Number of patients with colorectal cancer who undergo curative surgical resection where > 12 lymph nodes are pathologically examined. Total number of lymph nodes examined microscopically after final surgery is more than or equal to 12. Denominator = All patients with colorectal cancer who undergo curative surgical resection (with or without neoadjuvant short course radiotherapy). Exclusions = Patient with rectal cancer who undergo long course neo-adjuvant chemoradiotherapy or radiotherapy. Patients who undergo transanal endoscopic microsurgery or transanal resection of tumour. Colorectal Cancer Patients undergoing curative surgical resection have > 12 lymph nodes pathologically examined N N N N N Cohort Ineligible for this QPI Target 80% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 84.0% 96.2% 87.7% 87.4% 88.4% All Boards met this QPI. Following discussion at the Colorectal QPI National Meeting in February 2015, it was agreed it would be useful to consider looking at lymph node yield from node negative patients. This table shows the number of nodes examined for patients with Node negative (N0) disease. Lymph Node Yield in Node Negative BGH D&G Fife Lothian SCAN Patients N N N N N < to to > Total

24 QPI 5: Lymph Node Yield 100 % Patients Number of Patients having > 12 Lymph Nodes removed QPI Target 20 0 Health Board Comment: All boards are meeting the target for this QPI. This is a good marker of surgical quality in the SCAN region. As patient numbers are small, review after a 3 year cycle is recommended. 25

25 QPI 6: Neoadjuvant Radiotherapy Target= 90% Numerator = Number of patients with rectal cancer with a threatened or involved CRM on preoperative MRI undergoing surgery who receive long course neoadjuvant chemoradiotherapy¹. Denominator = All patients with rectal cancer with a threatened or involved CRM on preoperative MRI undergoing surgery. Exclusions = (a) Patients who refuse radiotherapy (b) Patients in whom radiotherapy is contraindicated (c) Patients who presented as an emergency for surgery Rectal Cancer Patients with threatened or involved CRM on preop MRI receive long course neoadjuvant chemoradiotherapy Borders N D&G N Fife N Lothian N SCAN N Cohort Ineligible for the QPI Target 90% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 100.0% 100.0% 71.4% 100.0% 91.3% Comments where QPI not met Fife: 2 patients: 1 had short course radiotherapy and one had no neo adjuvant treatment. 2 Not recorded for denominator - predicted CRM not recorded on MRI or MDT proforma. 26

26 QPI 6: Neoadjuvant Radiotherapy 100 % Patients Rectal Patients undergoing neoadjuvant chemoradiotherapy QPI Target 20 0 Health Board Comment: The CRM needs to be recorded in all pre-operative imaging. Changes at MDM level will assist with data collection. It is noted that there are very small numbers of patients being analysed in this QPI, giving rise to high percentage changes. Overall SCAN results are achieving the QPI. 27

27 QPI 7: Surgical Margins (i) Target = <5% Numerator = Number of patients with rectal cancer who undergo elective primary surgical resection or surgical resection following short course neoadjuvant radiotherapy in which tumour is present at the circumferential margin. Denominator = All patients with rectal cancer who undergo elective primary surgical resection or surgical resection following short course neoadjuvant radiotherapy. Exclusions = Patients who undergo transanal endoscopic microsurgery or transanal resection of tumour. Rectal Cancer Patients who undergo elective primary surgical resection or surgical resection following short course neo-adjuvant therapy N N N N N Cohort Ineligible for the QPI Target <5% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 0.0% 6.7% 0.0% 2.1% 1.7% Comments where QPI not met D&G: 1 patient had a palliative resection only. 28

28 QPI 7 (i) - Surgical Margins % Patients Primary surgery or surgery follow ing neoadjuvant short course XRT w ith +CRM QPI Target <5% 0 Health Board Comment: CRM needs to be recorded diligently pre-operatively. This QPI may require revision to exclude patient receiving palliative resections. Small numbers of patients being analysed are giving rise to high percentage changes. Overall SCAN is achieving this QPI. 29

29 QPI 7: Surgical Margins (ii) Target = <15% Numerator = Number of patients with rectal cancer who undergo elective surgical resection following neo-adjuvant long course radiotherapy or chemoradiotherapy in which tumour is present at the circumferential margin. Denominator = All patients with rectal cancer who undergo elective surgical resection following neo-adjuvant long course radiotherapy or chemoradiotherapy Exclusions = Patients who undergo transanal endoscopic microsurgery or transanal resection of tumour. All Rectal Cancer patients who undergo elective surgical resection following neoadjuvant long course radiotherapy or chemoradiotherapy N N N N N Cohort Ineligible for the QPI Target <15% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 0.0% 0.0% 16.7% 0.0% 4.5% Comments where QPI not met Fife: 1 patient: Treatment was long course radiotherapy and surgery with involvement of anterior CRM by 0.35 mm. 30

30 QPI 7 (ii) Surgical Margins % Patients Surgery follow ing neoadjuvant long course XRT or ChemoXRT QPI Target <15% 0 Health Board Comment: Again small numbers of patients being analysed are giving rise to high percentage changes. Overall SCAN is achieving this QPI. 31

31 QPI 8: Re-operation Rates Target = <10% (elective surgical resection) <15% (emergency surgical resection) Numerator = Number of patients with colorectal cancer who undergo surgical resection who return to theatre following initial surgical procedure (within 30 days of surgery) to deal with complications related to the index procedure. Denominator = All patients with colorectal cancer who undergo surgical resection. Exclusions = No exclusions. All colorectal cancer patients undergoing surgical resection who return to theatre within 30 days of their index procedure for complications - Index procedure Elective Borders N D&G N Fife N Lothian N SCAN N Cohort Ineligible for the QPI Target <10-15% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 0.0% 8.0% 2.3% 2.0% 2.6% All colorectal cancer patients undergoing surgical resection who return to theatre within 30 days of their index procedure for complications - Index procedure Emergency N N N N N Cohort Ineligible for the QPI Target <10-15% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 6.7% 0.0% 8.0% 4.8% 5.1% This QPI was met by all Boards. Comment: The QPI figures above have been generated by each Board, not ISD. Figures supplied by ISD were not felt to be an accurate measurement for this QPI. This QPI indicates a high level of primary surgery outcomes in SCAN. 32

32 QPI 9: Anastomotic Dehiscence (i) Target = <5% Numerator = Number of patients with colorectal cancer who undergo a surgical procedure involving anastomosis of the colon; or rectum; or patients with rectal cancer who undergo anterior resection and TME; having anastomotic leak requiring intervention (radiological or surgical). Denominator =.All patients with colorectal cancer who undergo a surgical procedure involving anastomosis of the colon. Exclusions = No exclusions. All patients with colorectal cancer who undergo a surgical procedure involving anastomosis of the colon N N N N N Cohort Ineligible for the QPI Target <5% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 0.0% 4.2% 1.4% 0.6% 1.3% This QPI was met by all Boards 33

33 QPI 9 (i): Colonic Anastomosis % Patients All patients undergoing anastomosis of the colon QPI Target <5% Health Board Comments: SCAN is achieving the target for this QPI. This is a very good result across all Boards reflecting the high standard of operating in the region. 34

34 QPI 9: Anastomotic Dehiscence (ii) Target = <10% Numerator = Number of patients with colorectal cancer who undergo a surgical procedure involving anastomosis of the colon; or rectum; or patients with rectal cancer who undergo anterior resection and TME; having anastomotic leak requiring intervention (radiological or surgical). Denominator = All patients with colorectal cancer who undergo a surgical procedure involving anastomosis of the rectum (including anterior resection with TME) Exclusions = Nil. All patients with colorectal cancer who undergo a surgical procedure involving anastomosis of the rectum N N N N N Cohort Ineligible for the QPI Target <10% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 4.0% 5.9% 2.0% 1.4% 2.2% This QPI was met by all Boards. 35

35 QPI 9 (ii): Rectal Anastomosis (including anterior resection with TME) % Patients Health Board All patients undergoing anastomosis of the rectum QPI Target <10% Comment: Overall, SCAN is achieving the target for this QPI. This is a very good result across all boards reflecting the high standard of operating in the region. 36

36 QPI 10 (i): 30 Day Mortality Following Surgical Resection Target = Elective surgical resection <5% Emergency surgical resection <15% Numerator = Number of patients with colorectal cancer who undergo emergency or elective surgical resection who die within 30 days of surgery. Denominator = All patients with colorectal cancer who undergo emergency or elective surgical resection. Exclusions = No exclusions Elective Surgery All patients with colorectal cancer who undergo elective surgical resection who die within 30 days of surgery N N N N N Cohort Ineligible for this QPI Elective Surgery <5% Numerator (elective surgery) Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 2.2% 1.3% 0.0% 0.4% 0.6% This QPI was met in all Boards QPI 10(i): 30 Day Mortality (Elective) % Patients Health Board 30 Day mortality follow ing elective surgery QPI Target <5% 37

37 QPI 10 (i): 30 Day Mortality Following Surgical Resection Emergency Surgery All patients with colorectal cancer who undergo emergency surgical resection who die within 30 days of surgery N N N N N Cohort Ineligible for this QPI Emergency Surgery <15% Numerator (emergency surgery) Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 6.7% 0.0% 7.4% 4.1% 4.8% This QPI was met in all Boards. QPI 10(i): 30 Day Mortality (Emergency) % Patients Day Mortality follow ing emergency surgery QPI Target <15% Health Board Comments: These low results reflect the high standard of operating in the SCAN region. In comparison to England and Wales combined elective and emergency figure of 2.9%, SCAN has a combined figure of 1.4%. 38

38 QPI 10 (ii): 90 Day Mortality Following Surgical Resection Target = Elective surgical resection <5% Emergency surgical resection <15% Numerator = Number of patients with colorectal cancer who undergo emergency or elective surgical resection who die within 90 days of surgery. Denominator = All patients with colorectal cancer who undergo emergency or elective surgical resection. Exclusions = No exclusions Elective Surgery All patients with colorectal cancer who undergo elective surgical resection who die within 90 days of surgery N N N N N Cohort Ineligible for this QPI Elective Surgery <5% Numerator (elective surgery) Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 6.5% 2.7% 0.0% 0.4% 1.1% Comments where QPI not met Borders: 3 patients: they have been reviewed by the Clinical Team. 39

39 QPI 10 (ii): 90 Day Mortality (Elective) % Patients Day mortality follow ing elective surgery QPI Target <5% 0 Health Board 40

40 QPI 10 (ii): 90 Day Mortality Following Surgical Resection Emergency Surgery All patients with colorectal cancer who undergo emergency surgical resection who die within 90 days of surgery N N N N N Cohort Ineligible for this QPI Emergency Surgery <15% Numerator (emergency surgery) Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 6.7% 11.1% 7.4% 9.5% 8.8% This QPI was met in all Boards. QPI 10 (ii): 90 Day Mortality (Emergency) % Patients Day Mortality follow ing emergency surgery QPI Target <15% Health Board Comment: These low results reflect the high standard of operating in the SCAN region. In comparison to England and Wales where the combined elective and emergency figure is 4.6%, SCAN has a combined figure of 2.6%. 41

41 ONCOLOGICAL TREATMENT OUTCOMES QPI 11: Adjuvant chemotherapy Target = Patients with Dukes C colorectal cancer 70% colorectal cancer 50% Patients with high risk Dukes B Numerator = Number of patients between 50 and 74 years of age at diagnosis with Dukes C, or high risk Dukes B, colorectal cancer who undergo surgical resection who receive adjuvant chemotherapy. Denominator = All patients between 50 and 74 years of age at diagnosis with Dukes C, or high risk Dukes B, colorectal cancer who undergo surgical resection. Exclusions = No exclusions. High Risk Dukes B N N N N N Cohort Ineligible for the QPI High Risk Dukes B - 50% Numerator - High Risk Dukes B Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 0.0% 50.0% 75.0% 64.3% 65.0% This QPI was met by all Boards 42

42 QPI 11: Adjuvant Chemotherapy (High Risk Dukes B) 100 % Patients Health Board High Risk Dukes B receiving adjuvant chemotherapy QPI Target <50% Comments: Borders did not have any High Risk Duke s B patients. Small figures being analysed result in big percentage changes. 43

43 QPI 11: Adjuvant chemotherapy Dukes C N N N N N Cohort Ineligible for the QPI Target: Dukes C - 70% Numerator - Dukes C Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 69.2% 100.0% 66.7% 68.1% 72.6% Comments where QPI not met Borders: 4 patients: 2 had palliative chemotherapy. 1 had cardiac issues. 1 had upper GI bleed and was not fit for treatment. Fife: 5 patients: 2 were considered unfit for chemotherapy; 1 had palliative chemo; 1 died post op; 1 had surgery for a synchronous cancer. Lothian: 23 patients: 11 had co-morbidities; 4 underwent palliative chemotherapy; 5 had ongoing post-operative problems; 1 patient died before treatment; 1 had a synchronous primary to be treated; in 1 the risks and toxicity of chemotherapy outweighed the benefits. 44

44 QPI 11: Adjuvant Chemotherapy (Dukes C) % Patients Health Board Dukes C receiving adjuvant chemotherapy QPI Target <70% Comment: All patients are considered in a MDM setting and clinical reasons for not achieving this QPI were sound. The SCAN Group queried the attainability of achieving the target level set. 45

45 QPI 12 (i): 30 Day Mortality Following Chemotherapy or Radiotherapy Target = <2% Numerator = Number of patients with colorectal cancer who undergo neo-adjuvant chemoradiotherapy, radiotherapy or adjuvant chemotherapy with curative intent who die within 30 days of treatment. Denominator = All patients with colorectal cancer who undergo neo-adjuvant chemoradiotherapy, radiotherapy or adjuvant chemotherapy with curative intent. Exclusions = No exclusions. All patients with colorectal cancer who undergo neoadjuvant chemotherapy, radiotherapy, or adjuvant chemotherapy with curative intent who die within 30 days of treatment N N N N N Cohort Ineligible for the QPI Target <2% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 6.3% 0.0% 0.0% 1.2% 1.1% Comments where QPI not met Borders: 1 patient died before commencement of treatment. 46

46 QPI 12(i): 30 Day Morality after Chemotherapy or Radiotherapy 20 % Patients Day Mortality follow ing Oncology treatment QPI Target <2% 0 Borders D&G Fife Lothian SCAN Health Board Comment: Small numbers are being analysed across the Boards. Overall, SCAN is meeting this QPI. 47

47 QPI 12 (ii): 90 Day Mortality Following Chemotherapy or Radiotherapy Target = <2% Numerator = Number of patients with colorectal cancer who undergo neo-adjuvant chemoradiotherapy, radiotherapy or adjuvant chemotherapy with curative intent who die within 90 days of treatment. Denominator = All patients with colorectal cancer who undergo neo-adjuvant chemoradiotherapy, radiotherapy or adjuvant chemotherapy with curative intent. Exclusions = No exclusions. All patients with colorectal cancer who undergo neoadjuvant chemotherapy, radiotherapy, or adjuvant chemotherapy with curative intent who die within 90 days of treatment N N N N N Cohort Ineligible for the QPI Target <2% Numerator Not Recorded for the Numerator Denominator Not Recorded for Exclusions Not Recorded for Denominator % Percentage 6.3% 0.0% 2.1% 1.2% 1.7% Comments where QPI not met Borders: Same patient as 30 day mortality Fife: 1 patient died 70 days post treatment. 48

48 QPI 12 (ii): 90 Day Morality after Chemotherapy or Radiotherapy 20 % Patients Day Mortality follow ing Oncology treatment QPI Target <2% 0 Health Board Comment: Small numbers in individual boards being analysed give rise to higher percentage change. Overall SCAN are meeting the target set. 49

49 CLINICAL TRIALS Clinical Trials Access Interventional Clinical Trials Target = 7.5% Numerator = Number of patients with Colorectal cancer enrolled in an interventional clinical trial Denominator = All patients with Colorectal cancer Exclusions = No exclusions Note: The clinical trials QPI will be measured utilising SCRN data and Cancer Registry data (5 year average of case ascertainment ) SCAN Target 7.5% Numerator 6 Not recorded for numerator 0 Denominator 1044 Not recorded for exclusions 0 Not recorded for denominator 0 % Performance 0.6% 50

50 Clinical Trials Access Translational Research Target = 15% Numerator = Number of patients with Colorectal cancer enrolled in translational research Denominator = All patients with Colorectal cancer Exclusions = No exclusions Note: The clinical trials QPI will be measured utilising SCRN data and Cancer Registry data (5 year average of case ascertainment ) SCAN Target 15% Numerator 238 Not recorded for numerator 0 Denominator 1044 Not recorded for exclusions 0 Not recorded for denominator 0 % Performance 22.8% 51

51 KEY CATEGORIES Table 1: Rectal v Other Colorectal Patients, percentage of patients undergoing Surgery No of Patients Diagnosed Number of patients diagnosed with rectal cancer Number of patients diagnosed with rectal cancer who had surgery All patients who had surgery Borders % % % D&G % % % Fife % % % Lothian % % % SCAN % % % Table 2: Rectal v Other Colorectal Patients No of Patients Diagnosed All patients who had definitive surgery Number of patients diagnosed with rectal cancer Number of patients diagnosed with rectal cancer who had definitive surgery Borders % % % D&G % % % Fife % % % Lothian % % % SCAN % % % Table 3: Emergency v Elective Surgery (Excluding non definitive surgery Endoscopic Treatment/Stents/Defunctioning Stomas/Bypass Surgery) All patients who had definitive surgery Emergency Elective Inapplicable Missing Data Borders % % 0 0.0% 0 0.0% D&G % % 0 0.0% 0 0.0% Fife % % 0 0.0% 0 0.0% Lothian % % 0 0.0% 0 0.0% SCAN % % 0 0.0% 0 0.0% 52

52 Table 4: Rectal Cancer Patients Emergency V Elective Surgery (Excluding non definitive surgery Endoscopic Treatment/Stents/Defunctioning Stomas/Bypass Surgery) All patients diagnosed with rectal cancer who had definitive surgery Emergency Elective Not Recorded Missing Data Borders % % 0 0.0% 0 0.0% D&G % % 0 0.0% 0 0.0% Fife % % 0 0.0% 0 0.0% Lothian % % 0 0.0% 0 0.0% SCAN % % 0 0.0% 0 0.0% Table 5: Intent of Surgery (Excluding non definitive surgery Endoscopic Treatment/Stents/Defunctioning Stomas/Bypass Surgery) All Patients who had Definitive Surgery Curative Palliative Not Recorded Missing Data Borders % % 0 0.0% 0 0.0% D&G % 4 4.9% 0 0.0% 0 0.0% Fife % % 0 0.0% 0 0.0% Lothian % % % 0 0.0% SCAN % % % 0 0.0% Table 6: Intent of Surgery Rectal Cancer N=All patients diagnosed with rectal cancer who had definitive surgery (Excluding non definitive surgery Endoscopic Treatment/Stents/Defunctioning Stomas/Bypass Surgery) All patients diagnosed with rectal cancer who had definitive surgery Curative Palliative Not Recorded Missing Data Borders % 0 0.0% 0 0.0% 0 0.0% D&G % 1 6.7% 0 0.0% 0 0.0% Fife % 4 8.5% 0 0.0% 0 0.0% Lothian % 4 5.0% 3 3.8% 0 0.0% SCAN % 9 5.6% 3 1.9% 0 0.0% 53

COLORECTAL CANCER Quality Performance Indicators (QPI) Comparative Report

COLORECTAL CANCER Quality Performance Indicators (QPI) Comparative Report SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT COLORECTAL CANCER 2016 2017 Quality Performance Indicators (QPI) Comparative Report Mr S Yalamarthi, NHS Fife, Lead Colorectal Cancer Clinician,

More information

COLORECTAL CANCER COMPARATIVE AUDIT REPORT SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT. Mr B.J. Mander SCAN Group Chair

COLORECTAL CANCER COMPARATIVE AUDIT REPORT SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT. Mr B.J. Mander SCAN Group Chair SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT COLORECTAL CANCER 2013-2014 COMPARATIVE AUDIT REPORT Mr B.J. Mander SCAN Group Chair Mr K Pal, NHS Borders Mr S Whitelaw, NHS Dumfries & Galloway

More information

Colorectal Cancer Quality Performance Indicators

Colorectal Cancer Quality Performance Indicators Publication Report Colorectal Cancer Quality Performance Indicators Patients diagnosed between April 2013 and March 2016 Publication date 27th June 2017 An Official Statistics Publication for Scotland

More information

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2016 March Published: March 2018

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2016 March Published: March 2018 Colorectal Cancer Managed Clinical Network Audit Report Colorectal Cancer Quality Performance Indicators Patients diagnosed April 2016 March 2017 Published: March 2018 Mr Michael Walker NOSCAN MCN Clinical

More information

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: July 2016

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: July 2016 NORTH OF SCOTLAND PLANNING GROUP Colorectal Cancer Managed Clinical Network Audit Report Colorectal Cancer Quality Performance Indicators Patients diagnosed April 2014 March 2015 Published: July 2016 Mr

More information

OESOPHAGO-GASTRIC CANCER 2016

OESOPHAGO-GASTRIC CANCER 2016 SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT OESOPHAGO-GASTRIC CANCER 2016 COMPARATIVE AUDIT REPORT Mr Peter Lamb SCAN Lead Upper GI Cancer Clinician Dr Jonathan Fletcher, Consultant Physician,

More information

COLORECTAL CANCER COMPARATIVE REPORT

COLORECTAL CANCER COMPARATIVE REPORT SA C07/11 W SE Scotland Cancer etwork Prospective Cancer Audit in South East Scotland COLORECTAL CACER COMPARATIVE REPORT Report on Patients Diagnosed January - December 2009 at Borders General Hospital

More information

Upper GI Cancer Quality Performance Indicators

Upper GI Cancer Quality Performance Indicators Publication Report Upper GI Cancer Quality Performance Indicators Patients diagnosed during January 2013 to December 2015 Publication date 28 th March 2017 An Official Statistics Publication for Scotland

More information

Head and Neck Cancer 2012 COMPARATIVE AUDIT REPORT

Head and Neck Cancer 2012 COMPARATIVE AUDIT REPORT SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT Head and Neck Cancer 2012 COMPARATIVE AUDIT REPORT Mr Guy Vernham, NHS Lothian SCAN Lead Clinician Head & Neck Cancer Mr J Morrison, Fife Mr

More information

Head and Neck Cancer 2010 COMPARATIVE AUDIT REPORT

Head and Neck Cancer 2010 COMPARATIVE AUDIT REPORT SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT Head and Neck Cancer 2010 COMPARATIVE AUDIT REPORT Mr Guy Vernham, NHS Lothian SCAN Lead Clinician Head & Neck Cancer Mr B Joshi, NHS Dumfries

More information

HEAD AND NECK CANCERS

HEAD AND NECK CANCERS SE Scotland Cancer Network HEAD AND NECK CANCERS SCAN COMPARATIVE ANNUAL AUDIT REPORT PATIENTS DIAGNOSED 1 January 31 December 2009 REPORT NUMBER: SA HN01/11 W Chair of SCAN Head & Neck Group: - Mr Guy

More information

HEAD AND NECK CANCERS

HEAD AND NECK CANCERS SE Scotland Cancer Network HEAD AND NECK CANCERS COMPARATIVE ANNUAL REPORT PATIENTS DIAGNOSED 1 January 31 December 2008 Final Report Sign off 31 st August 2010 Chair of Head & Neck Group: - Dr EJ Junor

More information

Colorectal Cancer Clinical Quality Performance Indicators

Colorectal Cancer Clinical Quality Performance Indicators Scottish Cancer Taskforce National Cancer Quality Steering Group Colorectal Cancer Clinical Quality Performance Indicators Published: December 2012 Updated: March 2015 (v2.1) May 2017 (v3.0) Published

More information

SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT

SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT BREAST CANCER 2016 COMPARATIVE AUDIT REPORT Mr Glyn Neades Chair SCAN Breast Group and Consultant Surgeon, NHS Fife & NHS Lothian Mr Ahmed

More information

Ovarian Cancer Quality Performance Indicators

Ovarian Cancer Quality Performance Indicators Ovarian Cancer Quality Performance Indicators Patients diagnosed between October 2013 and September 2016 Publication date 20 February 2018 An Official Statistics publication for Scotland This is an Official

More information

SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT

SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT BREAST CANCER 2013 COMPARATIVE AUDIT REPORT Mr Glyn Neades Chair Breast Group and Consultant Surgeon, NHS Fife Mr Matthew Barber, Consultant

More information

BREAST CANCER 2010 COMPARATIVE AUDIT REPORT

BREAST CANCER 2010 COMPARATIVE AUDIT REPORT SOUTH EAST SCOTLAND CANCER PROSPECTIVE CANCER AUDIT BREAST CANCER 2010 COMPARATIVE AUDIT REPORT Dr Jeremy Thomas, NHS Lothian Chair, Breast Group Miss Fawzia Ashkanani, NHS Dumfries and Galloway Mr Matthew

More information

SCAN Colorectal Group

SCAN Colorectal Group SCAN Colorectal Group Friday 1 st June 2012 14.15 16.15pm Oncology Seminar Room, WGH with videolink to Dumfries Present Alison Allen Angie Balfour Paul Fineron Stephen Glancy Mohammad Hosny Martin Keith

More information

Audit Report. Report of the 2014 Clinical Audit Data. North, South East and West of Scotland Cancer Networks

Audit Report. Report of the 2014 Clinical Audit Data. North, South East and West of Scotland Cancer Networks North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Audit Report Report of the 2014 Clinical Audit Data Professor Stephen Wigmore Consultant

More information

Ovarian Cancer Quality Performance Indicators (QPI) Comparative Report

Ovarian Cancer Quality Performance Indicators (QPI) Comparative Report SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT Ovarian Cancer Quality Performance Indicators (QPI) Comparative Report Dr Cameron Martin, SCAN Lead Ovarian Cancer Clinician Dr Scott

More information

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017 Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed January December 2016 Published: November 2017 Hardy Remmen NOSCAN Lung Cancer MCN Clinical

More information

Lung Cancer Quality Performance Indicators

Lung Cancer Quality Performance Indicators Publication Report Lung Cancer Quality Performance Indicators Patients diagnosed during April 2013 to December 2015 Publication date 28 th February 2017 RESTRICTED STATISTICS Release embargoed until Tuesday

More information

REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008

REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008 SE Scotland Cancer Network SCAN AUDIT REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008 Reports prepared by: Christine Maguire SCAN Cancer Audit Facilitator

More information

Testicular Cancer Quality Performance Indicators

Testicular Cancer Quality Performance Indicators Testicular Cancer Quality Performance Indicators Patients diagnosed between October 2014 and September 2017 Publication date 28 August 2018 An Official Statistics publication for Scotland This is an Official

More information

UROLOGICAL CANCER 2010 COMPARATIVE AUDIT REPORT

UROLOGICAL CANCER 2010 COMPARATIVE AUDIT REPORT SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT UROLOGICAL CANCER 2010 COMPARATIVE AUDIT REPORT Dr Prasad Bollina, NHS Lothian SCAN Lead Urology Cancer Clinician Dr Prasad Bollina, NHS Lothian

More information

Audit Report Report of the 2015 Clinical Audit Data

Audit Report Report of the 2015 Clinical Audit Data North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Audit Report Report of the 2015 Clinical Audit Data Professor Stephen Wigmore Consultant

More information

ADJUVANT CHEMOTHERAPY...

ADJUVANT CHEMOTHERAPY... Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED

More information

LUNG CANCER 2010 COMPARATIVE AUDIT REPORT

LUNG CANCER 2010 COMPARATIVE AUDIT REPORT SOUTHEAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT LUNG CANCER 2010 COMPARATIVE AUDIT REPORT Dr Ron Fergusson, NHS Lothian SCAN Lead Lung Cancer Clinician Dr Jakki Faccenda, NHS Borders Dr Paul

More information

S E SCOTLAND CANCER NETWORK REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2009

S E SCOTLAND CANCER NETWORK REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2009 SE Scotland Cancer Network SCAN AUDIT S E SCOTLAND CANCER NETWORK REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2009 Dr John M Davies SCAN and NHS Lothian Dr

More information

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016 NORTH OF SCOTLAND PLANNING GROUP Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed April 2014 March 2015 Published: May 2016 Mr Hardy Remmen

More information

SCAN Colorectal Group

SCAN Colorectal Group SCAN Colorectal Group Friday 9 th August 2013 14.15 16.15pm Oncology Seminar Room, WGH with videolink to Dumfries Present Lorna Bruce Sarah Buchan Paul Fineron Martin Keith Christina Lilley Joyce Livingston

More information

National Breast Cancer Audit next steps. Martin Lee

National Breast Cancer Audit next steps. Martin Lee National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast

More information

SE SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT LUNG CANCER REPORT ON PATIENTS DIAGNOSED 1 JANUARY 31 DECEMBER 2009

SE SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT LUNG CANCER REPORT ON PATIENTS DIAGNOSED 1 JANUARY 31 DECEMBER 2009 SE SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT LUNG CANCER REPORT ON PATIENTS DIAGNOSED 1 JANUARY 31 DECEMBER 2009 Dr Ron Fergusson SCAN Lead Lung Cancer Clinician Dr Colin Selby Dr Jakki Faccenda

More information

Activity Report April 2012 to March 2013

Activity Report April 2012 to March 2013 North, South East and West of Scotland Cancer Networks Brain/Central Nervous System Tumours National Managed Clinical Network Activity Report April 2012 to March 2013 Professor Roy Rampling Emeritus Professor

More information

SCAN Colorectal Group

SCAN Colorectal Group DRAFT SCAN Colorectal Group Friday 6 th December 2013 14.15 16.15pm Oncology Seminar Room, WGH with videolink to Victoria Hospital, Kirkcaldy. Present Ibrahim Amin Angie Balfour Sarah Buchan Paul Fineron

More information

Audit Report. Upper GI Cancer Quality Performance Indicators. Report of the 2016 Clinical Audit Data. West of Scotland Cancer Network

Audit Report. Upper GI Cancer Quality Performance Indicators. Report of the 2016 Clinical Audit Data. West of Scotland Cancer Network Upper Gastro-intestinal Cancer Managed Clinical Network Audit Report Upper GI Cancer Quality Performance Indicators Report of the 216 Clinical Audit Data Mr Matthew Forshaw MCN Clinical Lead Tracey Cole

More information

OVARIAN CANCER 2011 COMPARATIVE AUDIT REPORT

OVARIAN CANCER 2011 COMPARATIVE AUDIT REPORT SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT OVARIAN CANCER 2011 COMPARATIVE AUDIT REPORT Dr Melanie Mackean, NHS Lothian SCAN Lead Ovarian Cancer Clinician Dr Jane Macnab, NHS Fife Dr Scott

More information

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: February 2018

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: February 2018 Breast Cancer Managed Clinical Network Audit Report Breast Cancer Quality Performance Indicators Patients diagnosed during 2016 Published: February 2018 Mr Douglas Brown NOSCAN Breast Cancer MCN Clinical

More information

Activity Report April 2012 March 2013

Activity Report April 2012 March 2013 North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Activity Report April 2012 March 2013 Mr Colin McKay Consultant Surgeon NMCN Clinical

More information

Activity Report April 2013 March 2014

Activity Report April 2013 March 2014 North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Activity Report April 2013 March 2014 Mr Colin McKay Consultant Surgeon NMCN Clinical

More information

UROLOGY CANCER 2009 COMPARATIVE AUDIT REPORT

UROLOGY CANCER 2009 COMPARATIVE AUDIT REPORT Urological Cancer Audit 2009 SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT UROLOGY CANCER 2009 COMPARATIVE AUDIT REPORT Dr Prasad Bollina, NHS Lothian SCAN Lead Urology Cancer Clinician Dr

More information

Audit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016

Audit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016 Gynaecology Managed Clinical Network NORTH OF SCOTLAND PLANNING GROUP Audit Report Cervical Cancer Quality Performance Indicators Patients diagnosed October 2014 September 2015 Published: September 2016

More information

Audit Report Endometrial & Cervical Cancer Quality Performance Indicators

Audit Report Endometrial & Cervical Cancer Quality Performance Indicators Gynaecological Cancer Managed Clinical Network Audit Report Endometrial & Cervical Cancer Quality Performance Indicators Clinical Audit Data: 01 October 2014 to 30 September 2015 Nadeem Siddiqui Consultant

More information

Activity Report April 2012 March 2013

Activity Report April 2012 March 2013 Colorectal Cancer Managed Clinical Network Activity Report April 2012 March 2013 Paul Horgan Professor of Surgery MCN Clinical Lead Kevin Campbell Network Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION

More information

Acute Leukaemia Quality Performance Indicators

Acute Leukaemia Quality Performance Indicators Acute Leukaemia Quality Performance Indicators Patients diagnosed between July 2014 and June 2017 Publication date 19 June 2018 An Official Statistics publication for Scotland This is an Official Statistics

More information

Report prepared on behalf of the Scottish Head and Neck Cancer Networks by the WoSCAN Information Team

Report prepared on behalf of the Scottish Head and Neck Cancer Networks by the WoSCAN Information Team Scottish Head and Neck Cancer Networks Report of the 2011 Clinical Audit Data Presented at the National Head and Neck Cancer Education Day 26th October 2012 Report prepared on behalf of the Scottish Head

More information

SCAN Skin Group Friday 1 st November 2013

SCAN Skin Group Friday 1 st November 2013 SCAN Skin Group Friday 1 st November 2013 Dermatology Seminar Room, Lauriston Buildings with videolinks to Oncology Seminar Room, Western General Hospital and Borders General Hospital. MINUTES Present

More information

SCAN Lung Group Wednesday 25 th September pm

SCAN Lung Group Wednesday 25 th September pm DRAFT SCAN Lung Group Wednesday 25 th September 2013 14.15 16.15pm Telepresence Suite, Western General Hospital, Edinburgh with videolinks to Borders and Dumfries Present Sandra Bagnall Mimica Bjelogrlic

More information

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: December 2015 NORTH OF SCOTLAND PLANNING GROUP

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: December 2015 NORTH OF SCOTLAND PLANNING GROUP NORTH OF SCOTLAND PLANNING GROUP Breast Cancer Managed Clinical Network Audit Report Breast Cancer Quality Performance Indicators Patients diagnosed during Published: December 2015 Mr Douglas Brown NOSCAN

More information

Activity Report April 2013 March 2014

Activity Report April 2013 March 2014 North, South East and West of Scotland Cancer Networks Sarcoma National Managed Clinical Network Activity Report April 2013 March 2014 Dr Jeff White Consultant Oncologist NMCN Clinical Lead Lindsay Campbell

More information

Audit Report. Bladder Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network

Audit Report. Bladder Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network Urological Cancer Managed Clinical Network Audit Report Bladder Cancer Quality Performance Indicators Clinical Audit Data: 01 April 2015 to 31 March 2016 Mr Gren Oades MCN Clinical Lead Tom Kane MCN Manager

More information

The Binational Colorectal Cancer Audit. A/Prof Paul McMurrick Head, Cabrini Monash University Dept of Surgery 2017

The Binational Colorectal Cancer Audit. A/Prof Paul McMurrick Head, Cabrini Monash University Dept of Surgery 2017 The Binational Colorectal Cancer Audit A/Prof Paul McMurrick Head, Cabrini Monash University Dept of Surgery 2017 Binational Colorectal Cancer Database 2010 First Patient 2011 Contract between CMUDS and

More information

Clinical Audit Data: 01 October 2015 to 30 September West of Scotland Cancer Network. Gynaecological Cancer Managed Clinical Network

Clinical Audit Data: 01 October 2015 to 30 September West of Scotland Cancer Network. Gynaecological Cancer Managed Clinical Network Gynaecological Cancer Managed Clinical Network Audit Report Ovarian Cancer Quality Performance Indicators Cervical Cancer Quality Performance Indicators Endometrial Cancer Quality Performance Indicators

More information

Head and Neck QPI Group Audit Report Head and Neck Quality Performance Indicators Consultant Clinical Oncologist, NHS Grampian

Head and Neck QPI Group Audit Report Head and Neck Quality Performance Indicators Consultant Clinical Oncologist, NHS Grampian Head and Neck QPI Group Audit Report Head and Neck Quality Performance Indicators Patients diagnosed April 2016 March 2017 Published: February 2018 Dr Rafael Moleron Consultant Clinical Oncologist, NHS

More information

Activity Report July 2012 June 2013

Activity Report July 2012 June 2013 Urological Cancers Managed Clinical Network Activity Report July 2012 June 2013 Mr Seamus Teahan Consultant Urologist MCN Clinical Lead Tom Kane MCN Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION

More information

Bowel Cancer Information Leaflet THE DIGESTIVE SYSTEM

Bowel Cancer Information Leaflet THE DIGESTIVE SYSTEM THE DIGESTIVE SYSTEM This factsheet is about bowel cancer Throughout our lives, the lining of the bowel constantly renews itself. This lining contains many millions of tiny cells, which grow, serve their

More information

MELANOMA 2011 COMPARATIVE AUDIT REPORT

MELANOMA 2011 COMPARATIVE AUDIT REPORT SOUTHEAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT MELANOMA 2011 COMPARATIVE AUDIT REPORT Report Number: SA Skin 03 13 Dr Daniel Kemmett, NHS Borders and NHS Lothian SCAN Lead Skin Cancer Clinician

More information

Data Definitions for the National Minimum Core Dataset to support the Introduction of Colorectal Quality Performance Indicators

Data Definitions for the National Minimum Core Dataset to support the Introduction of Colorectal Quality Performance Indicators Colorectal Cancer Data Definitions for the National Minimum Core Dataset to support the Introduction of Colorectal Quality Performance Indicators Definitions developed by ISD Scotland in collaboration

More information

Audit Report. Testicular Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network

Audit Report. Testicular Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network Urological Cancer Managed Clinical Network Audit Report Testicular Cancer Quality Performance Indicators Clinical Audit Data: 01 October 2014 to 30 September 2015 Mr Gren Oades MCN Clinical Lead Tom Kane

More information

Clinical guideline Published: 1 November 2011 nice.org.uk/guidance/cg131

Clinical guideline Published: 1 November 2011 nice.org.uk/guidance/cg131 Colorectal cancer: diagnosis and management Clinical guideline Published: 1 November 2011 nice.org.uk/guidance/cg131 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Activity Report April 2014 March 2015

Activity Report April 2014 March 2015 North, South East and West of Scotland Cancer Networks Brain/Central Nervous System Tumours National Managed Clinical Network Activity Report April 2014 March 2015 Dr Avinash Kanodia Consultant Radiologist

More information

Ovarian Cancer Audit Comparative Annual Report 01/01/ /12/2009

Ovarian Cancer Audit Comparative Annual Report 01/01/ /12/2009 SE Scotland Cancer Network SCAN AUDIT Ovarian Cancer Audit Comparative Annual Report 01/01/2009 31/12/2009 S E Scotland Cancer Network (SCAN) (Excluding Dumfries and Galloway) NHS Borders NHS Fife NHS

More information

Audit Report. Brain and CNS Cancer Quality Performance Indicators. Report of the 2014 Clinical Audit Data

Audit Report. Brain and CNS Cancer Quality Performance Indicators. Report of the 2014 Clinical Audit Data North, South East and West of Scotland Cancer Networks Neuro-Oncology Cancers Audit Report Brain and CNS Cancer Quality Performance Indicators Report of the 2014 Clinical Audit Data Dr Avinash Kanodia

More information

Annual Report April 2016 March 2017

Annual Report April 2016 March 2017 North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Annual Report April 2016 March 2017 Professor Stephen Wigmore Consultant Surgeon

More information

Bowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer

Bowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer Bowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer Based on findings from the National Bowel Cancer Audit Background How are patients diagnosed?

More information

Audit Report. Endometrial Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016

Audit Report. Endometrial Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016 Gynaecology Managed Clinical Network NORTH OF SCOTLAND PLANNING GROUP Audit Report Endometrial Cancer Quality Performance Indicators Patients diagnosed October 2014 September 2015 Published: September

More information

Audit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2015 September Published: September 2017

Audit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2015 September Published: September 2017 Gynaecology Managed Clinical Network Audit Report Cervical Cancer Quality Performance Indicators Patients diagnosed October 2015 September 2016 Published: September 2017 Dr Ann-Maree Kennedy MCN Clinical

More information

Northern Ireland Bowel Cancer Screening Programme. Pathways. Version 4 1 st October 2013

Northern Ireland Bowel Cancer Screening Programme. Pathways. Version 4 1 st October 2013 Northern Ireland Bowel Cancer Screening Programme Pathways These changes will be version controlled, led by the Quality Assurance Director for the Programme. Any updated versions will be circulated and

More information

Audit Report Report of the 2012 Clinical Audit Data

Audit Report Report of the 2012 Clinical Audit Data Urological Cancer Managed Clinical Network Audit Report Report of the 2012 Clinical Audit Data Mr Seamus Teahan MCN Clinical Lead Tom Kane MCN Manager Sandie Ker Information Officer Urological Cancer Audit

More information

Follow up The way ahead. John Griffith

Follow up The way ahead. John Griffith Follow up The way ahead John Griffith Key Emerging Principles Risk stratified pathways of care Personalised care plan and treatment summary with a hand held record Information and education Remote monitoring

More information

Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh

Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh What is Early rectal cancer? pt1t2n0m0 Predictors for LN involvement Size Depth Intramural

More information

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT MDT Lead Clinician CSCCN PORTSMOUTH HOSPITALS Portsmouth Colorectal MDT (11-2D-1) - 2011/12 Daniel OLeary Compliance Self Assessment COLORECTAL

More information

Audit Report Acute Leukaemia Quality Performance Indicators

Audit Report Acute Leukaemia Quality Performance Indicators Haemato-oncology Managed Clinical Network Audit Report Acute Leukaemia Quality Performance Indicators Clinical Audit Data: 01 July 2014 to 30 June 2017 Dr Mark Drummond Consultant Haematologist MCN Clinical

More information

SCAN Skin Group Friday 24 th February 2012

SCAN Skin Group Friday 24 th February 2012 DRAFT SCAN Skin Group Friday 24 th February 2012 Dermatology Seminar Room, Lauriston Building with videolink to Borders General Hospital MINUTES Present Alex Holme Daniel Kemmett Chair Simone Laube Kate

More information

Treatment strategy of metastatic rectal cancer

Treatment strategy of metastatic rectal cancer 35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent

More information

State-of-the-art of surgery for resectable primary tumors

State-of-the-art of surgery for resectable primary tumors Early colorectal cancer State-of-the-art of surgery for resectable primary tumors (Special focus on rectal cancer surgery) Stefan Heinrich & Hauke Lang Department of General, Visceral and University Hospital

More information

Audit Report Lymphoma Quality Performance Indicators

Audit Report Lymphoma Quality Performance Indicators West of Scotland Cancer Network Haemato-oncology Managed Clinical Network Audit Report Lymphoma Quality Performance Indicators Clinical Audit Data: 01 October 2016 to 30 September 2017 Dr Grant McQuaker

More information

Audit Report. Testicular Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network

Audit Report. Testicular Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network West of Scotland Cancer Network Urological Cancer Managed Clinical Network Audit Report Testicular Cancer Quality Performance Indicators Clinical Audit Data: 01 October 2015 to 30 September 2016 Mr Gren

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: diagnosis and management of colorectal cancer 1.1 Short title Colorectal cancer 2 The remit The Department

More information

Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012

Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012 Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012 Version Control This is a controlled document please destroy all previous versions on receipt

More information

RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY

RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY COLORECTAL CLINICAL SUBGROUP RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY Finalised by: Dr Simon Gollins Mr Andrew Renehan Dr Mark Saunders Mr Nigel Scott Dr Shabbir

More information

COLORECTAL CARCINOMA

COLORECTAL CARCINOMA QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian

More information

abcdefghijklmnopqrstu

abcdefghijklmnopqrstu CMO and Public Health Directorate Health Improvement Strategy Division Dear Colleague Scottish Abdominal Aortic Aneurysm Screening Programme This CEL outlines the plan for the implementation of the AAA

More information

Colorectal Pathway Board (Clinical Subgroup): Imaging Guidelines September 2015

Colorectal Pathway Board (Clinical Subgroup): Imaging Guidelines September 2015 Colorectal Pathway Board (Clinical Subgroup): Imaging Guidelines September 2015 1 Contents Page No. 1. Objective 3 2. Imaging Techniques 3 3. Staging of Colorectal Cancer 5 4. Radiological Reporting 6

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND

More information

Activity Report March 2013 February 2014

Activity Report March 2013 February 2014 West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland

More information

National Bowel Cancer Audit. Detection and management of outliers: Clinical Outcomes Publication

National Bowel Cancer Audit. Detection and management of outliers: Clinical Outcomes Publication National Bowel Cancer Audit Detection and management of outliers: Clinical Outcomes Publication November 2017 1 National Bowel Cancer Audit (NBOCA) Detection and management of outliers Clinical Outcomes

More information

BOWEL CANCER. Causes of bowel cancer

BOWEL CANCER. Causes of bowel cancer A cancer is an abnormality in an organ that grows without control. The growth is often quite slow, but will continue unabated until it is detected. It can cause symptoms by its presence in the organ or

More information

Guideline for the Management of Vulval Cancer

Guideline for the Management of Vulval Cancer Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11

More information

Activity Report April 2012 March 2013

Activity Report April 2012 March 2013 Gynaecological Cancer Managed Clinical Network Activity Report April 2012 March 2013 Nadeem Siddiqui MCN Clinical Lead Kevin Campbell Network Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION 4 2.

More information

Audit Report Report of the 2011 Clinical Audit Data

Audit Report Report of the 2011 Clinical Audit Data Lung Cancer Managed Clinical Network Audit Report Report of the 2011 Clinical Audit Data Dr Richard Jones Consultant Clinical Oncologist MCN Clinical Lead Kevin Campbell MCN Manager Julie McMahon Information

More information

National Bowel Cancer Audit Supplementary Report 2011

National Bowel Cancer Audit Supplementary Report 2011 National Bowel Cancer Audit Supplementary Report 2011 This Supplementary Report contains data from the 2009/2010 reporting period which covers patients in England with a diagnosis date from 1 August 2009

More information

Colorectal Cancer. Mark Chapman. MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist

Colorectal Cancer. Mark Chapman. MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist Colorectal Cancer Mark Chapman MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist Overview Epidemiology of colorectal cancer Adenoma carcinoma sequence Tumour diagnosis & staging Treatment

More information

Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases

Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Date: April 2015 Date for review: April 2018 1. Principles The recognised specialist HPB MDT for Greater

More information

COLON AND RECTAL CANCER

COLON AND RECTAL CANCER COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal

More information

COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE

COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE PROFESSOR OF SURGERY & DIRECTOR, PROFESSIONAL DEVELOPMENT CENTRE J I N N A H S I N D H M E D I C A L U N I V E R S I T Y faisal.siddiqui@jsmu.edu.pk

More information

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE The Condition 1. The condition should be an important health problem Colorectal

More information

Screening & Surveillance Guidelines

Screening & Surveillance Guidelines Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following

More information

Radiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre

Radiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre Radiotherapy for Rectal Cancer Kevin Palumbo Adelaide Radiotherapy Centre Overview CRC are common (3 rd commonest cancer) rectal Ca approx 25-30% of all CRC. Presentation PR bleeding: beware attributing

More information

PATHOLOGY GROUP GUIDELINES FOR THE EXAMINATION AND REPORTING OF COLORECTAL CANCER SPECIMENS

PATHOLOGY GROUP GUIDELINES FOR THE EXAMINATION AND REPORTING OF COLORECTAL CANCER SPECIMENS PATHOLOGY GROUP GUIDELINES FOR THE EXAMINATION AND REPORTING OF COLORECTAL CANCER SPECIMENS Produced by: Address: Yorkshire Cancer Network Pathology Group Arthington House, Cookridge Hospital, Hospital

More information